These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 9031453

  • 41. Effects of various fibrates on serum alkaline phosphatase activity.
    Ganotakis E, Tsimihodimos V, Bairaktari E, Rizos E, Athyros V, Seferiades C, Elisaf M.
    Atherosclerosis; 2002 Nov; 165(1):187-8. PubMed ID: 12208487
    [No Abstract] [Full Text] [Related]

  • 42. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP, Jagroon IA.
    Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract] [Full Text] [Related]

  • 43. [Acute rhabdomyolysis associated with digestive disorders during a voluntary overdose of ciprofibrate].
    Giraud O, Chanu B, Farge D, Parrot F, Brestescher C, Rouffy J.
    Gastroenterol Clin Biol; 1995 Feb; 19(2):231-2. PubMed ID: 7750722
    [No Abstract] [Full Text] [Related]

  • 44. Methods of chromatographic determination of medicines decreasing the level of cholesterol.
    Kublin E, Kaczmarska-Graczyk B, Malanowicz E, Mazurek AP.
    Acta Pol Pharm; 2010 Feb; 67(5):455-61. PubMed ID: 20873411
    [Abstract] [Full Text] [Related]

  • 45. [The pharmacokinetics of antilipemic agents. 8. Unequivocal characterization of ciprofibrate-O-beta-d-glucuronide].
    Oelschläger H, Kohl C, Armstrong DW, Rothley D.
    Arch Pharm (Weinheim); 1991 Aug; 324(8):505-8. PubMed ID: 1781732
    [Abstract] [Full Text] [Related]

  • 46. [Clinical trial of a new drug for the treatment of atherosclerosis: pirozadil (722-D) (author's transl)].
    Marín Plaza R, Díaz González JM, Varela de Seijas JR.
    Med Clin (Barc); 1982 May 16; 78(10):427-32. PubMed ID: 7047924
    [No Abstract] [Full Text] [Related]

  • 47. Effects of diet, drugs, and genes on plasma fibrinogen levels.
    de Maat MP.
    Ann N Y Acad Sci; 2001 May 16; 936():509-21. PubMed ID: 11460508
    [Abstract] [Full Text] [Related]

  • 48. Need for treatment of elevated plasma fibrinogen levels in cerebrovascular disease.
    Clark WM, Coull BM, Beamer NB.
    Heart Dis Stroke; 1993 May 16; 2(6):503-6. PubMed ID: 8137058
    [No Abstract] [Full Text] [Related]

  • 49. [Synthesis and physico-chemical characterisation of some new derivatives of rutoside and clofibric acid].
    Lupaşcu D, Profire L, Dănilă G.
    Rev Med Chir Soc Med Nat Iasi; 2006 May 16; 110(1):224-7. PubMed ID: 19292111
    [Abstract] [Full Text] [Related]

  • 50. Compliance with medication in the Helsinki Heart Study.
    Mäenpää H, Manninen V, Heinonen OP.
    Eur J Clin Pharmacol; 1992 May 16; 42(1):15-9. PubMed ID: 1541311
    [Abstract] [Full Text] [Related]

  • 51. Gemfibrozil--a new lipid lowering agent.
    Hodges RM.
    Proc R Soc Med; 1976 May 16; 69 Suppl 2(Suppl 2):1-2. PubMed ID: 798192
    [No Abstract] [Full Text] [Related]

  • 52. Fibrinogen: a predictor of vascular disease.
    Kakafika AI, Liberopoulos EN, Mikhailidis DP.
    Curr Pharm Des; 2007 May 16; 13(16):1647-59. PubMed ID: 17584095
    [Abstract] [Full Text] [Related]

  • 53. Drugs affecting plasma fibrinogen levels.
    di Minno G, Mancini M.
    Cardiovasc Drugs Ther; 1992 Feb 16; 6(1):25-7. PubMed ID: 1576094
    [Abstract] [Full Text] [Related]

  • 54. Effects of cancer chemotherapy on the blood fibrinogen concentrations of cancer patients.
    Lu DY, Chen XL, Cao JY, Li Z, Xue HW, Luo LJ, Xu B.
    J Int Med Res; 2000 Feb 16; 28(6):313-7. PubMed ID: 11191725
    [Abstract] [Full Text] [Related]

  • 55. Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies.
    Margaglione M, Grandone E, Mancini FP, Di Minno G.
    Prog Drug Res; 1996 Feb 16; 46():169-81. PubMed ID: 8754205
    [Abstract] [Full Text] [Related]

  • 56. Macromolecular protein complex: a new way to understand the fibrinogen lowering effect of glycosaminoglycans?
    Ceriello A.
    Thromb Haemost; 1994 Dec 16; 72(6):985-6. PubMed ID: 7740473
    [No Abstract] [Full Text] [Related]

  • 57. Fibrates for treatment of the metabolic syndrome.
    Maki KC.
    Curr Atheroscler Rep; 2004 Jan 16; 6(1):45-51. PubMed ID: 14662107
    [Abstract] [Full Text] [Related]

  • 58. Vascular inflammation as a therapeutic target for prevention of cardiovascular disease.
    Clark LT.
    Curr Atheroscler Rep; 2002 Mar 16; 4(2):77-81. PubMed ID: 11822969
    [No Abstract] [Full Text] [Related]

  • 59. Statins and inflammatory markers.
    Case CC, Ballantyne CM.
    Curr Atheroscler Rep; 2002 Jan 16; 4(1):42-7. PubMed ID: 11772421
    [Abstract] [Full Text] [Related]

  • 60. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia.
    Spencer CM, Barradell LB.
    Drugs; 1996 Jun 16; 51(6):982-1018. PubMed ID: 8736620
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.